Zepbound®

Branded GLP-1. Weekly self-injection pen (Eli Lilly)

FDA-approved dual GIP and GLP-1 receptor agonist for chronic weight management.

Dosing: Set by your prescriber and adjusted over time based on how you respond.

Best for: Patients whose insurance covers Zepbound® and who want the branded dual-incretin product.

Key points

• FDA-approved for chronic weight management
• SURMOUNT-1 trial reference: about 21% average total body weight loss at 72 weeks
• Dispensed through licensed pharmacies with HELiXVi clinician oversight

Considerations

• Insurance coverage varies significantly
• GI side effects most common during dose escalation
• Prescription-only

Prescription treatment requires an online consultation with a licensed HELiXVi clinician. Individual results vary.

Start your free consultation right now

No clinic visit. Licensed US clinicians. Dispatched within 24 hours of your consultation and payment.

See the full weight loss program